Ramsay Health Care shares (ASX: RHC) extended an impressive recovery run, with the price touching a two-and-a-half-year high of A$54.22 on Thursday, capping a 22% jump since late August and a year-to-date gain of 57%.

The support for RHC shares comes amid a mix of strong full-year earnings, a transformative corporate restructure, and a strategic domestic acquisition that have fundamentally reframed the investment case.

Yesterday’s intraday high of A$54.22 marks a break above recent resistance, and brings gain to 2.7% for the week so far into the final trading session. The move is all the more striking when measured against Ramsay’s 52-week low of A$30.39, a trough that now feels like a distant memory for shareholders who held through a prolonged period of margin pressure and European underperformance.

The rally accelerated sharply following the company’s FY26 full-year results on August 27, and has continued to build as markets digest the structural implications of the pending Ramsay Santé demerger.

 

Top Australian Brokers

Driving Ramsay Health Care Shares To Highs

Ramsay’s FY26 results delivered the kind of numbers that markets had been waiting for after several years of post-pandemic operational complexity. Underlying net profit after tax rose 19.3% year-over-year to A$364.1 million, or 22.9% on a constant currency basis, while group revenue reached A$18.6 billion.

Underlying EBIT grew 11.8% to A$1.16 billion, with the Australian division contributing EBIT growth of 11.2%. Perhaps most encouragingly for those focused on the quality of earnings, group underlying EBIT margin improved by 30 basis points to 6.2%, driven by higher patient volumes, better operating theatre utilisation, improved private health insurer contract pricing, and tighter cost discipline across the business. The board rewarded shareholders with a 13.8% increase in the full-year dividend to A$0.91 per share, signalling confidence in the sustainability of the earnings recovery.

What Lay Ahead

The structural story attracting significant market attention is the planned separation of Ramsay Santé, the company’s European hospital subsidiary in which it holds a 52.79% controlling stake. Rather than pursuing a trade sale, Ramsay has opted for an in-specie distribution of CHESS Depositary Interests directly to existing RHC shareholders. A shareholder vote is scheduled for November, with implementation targeted for December.

The rationale is straightforward: European operations, particularly in France, have been weighed down by rigid government-set administrative tariffs and persistent wage inflation, acting as a structural drag on group margins. Separating these assets leaves the ASX-listed entity as a focused, higher-margin Australian hospital business, which markets have responded to enthusiastically.

Adding further weight to the domestic growth narrative, Ramsay announced the acquisition of the National Capital Private Hospital in Canberra for A$251 million. Management has flagged the transaction as earnings-accretive within its first 12 months of operation, demonstrating a willingness to deploy capital selectively into high-demand metropolitan markets where private hospital capacity remains constrained.

Ramsay Health Care’s rise to a two-and-a-half-year high is a well-earned reflection of genuine operational improvement, a strategically sound corporate restructure, and renewed confidence in the Australian private hospital sector, but with shares now trading above consensus price targets at a premium multiple, bears point to valuation as a point of interest. Plenty to watch as the weekend approaches, but momentum here is proving tricky to slow.

Bull Case:

  • FY26 underlying NPAT rose 19.3%, confirming a durable domestic earnings recovery.
  • Ramsay Santé demerger creates a pure-play Australian hospital operator with superior margins.
  • A$251M Canberra acquisition is accretive in Year 1, reinforcing disciplined domestic growth.

Bear Case:

  • Shares trade above consensus analyst targets near A$50.88, suggesting limited near-term upside.
  • Forward P/E of 33-38x leaves little margin for error on earnings delivery.
  • A$49M director share sale signals potential insider caution at current price levels.
The Bull Team
The Bull Team is a group of finance writers and journalists that provide commentary and insights on the Australian stock market and beyond.